Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Símbolo de cotizaciónLLY
Nombre de la empresaEli Lilly and Co
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)
Número de empleados47000
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 09
DirecciónLilly Corporate Ctr
CiudadINDIANAPOLIS
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal46285
Teléfono13172762000
Sitio Webhttps://www.lilly.com/
Símbolo de cotizaciónLLY
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)